Berenberg Bank Reaffirms “Buy” Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reissued by research analysts at Berenberg Bank in a note issued to investors on Friday, Marketbeat.com reports. They currently have a GBX 140 ($1.86) target price on the biopharmaceutical company’s stock. Berenberg Bank’s price target would indicate a potential downside of 98.64% from the stock’s previous close.

Several other equities analysts have also weighed in on the company. Shore Capital restated a “buy” rating on shares of AstraZeneca in a research note on Tuesday, April 29th. JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a research report on Wednesday, February 19th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of GBX 6,303.50 ($83.82).

AstraZeneca Stock Performance

Shares of AstraZeneca stock traded up GBX 72 ($0.96) during trading on Friday, hitting £103.02 ($136.99). 231,203,328 shares of the company’s stock traded hands, compared to its average volume of 18,542,820. The business has a 50-day simple moving average of £107.21 and a 200-day simple moving average of £108.62. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. AstraZeneca has a 1 year low of GBX 9,573.51 ($127.31) and a 1 year high of £133.88 ($178.03). The stock has a market capitalization of £198.21 billion, a P/E ratio of 28.24, a PEG ratio of 0.86 and a beta of 0.17.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.